Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
ERECTILE DYSFUNCTION THERAPEUTICS PIPELINE ANALYSIS
• Erectile dysfunction therapeutics also called as impotence, is nothing but the inability or a form of sexual dysfunction where a man cannot retain a firm erection of the penis for coitus.
• Erectile dysfunction is more likely to affect people with blood clots, low blood pressure, and heart problems. It can be cured with appropriate medications.
• The predisposing factors are tobacco usage, injuries, overweight, drug and alcohol use. And medications include antidepressants, antihistamines and also include medications to treat high blood pressure, and pain or prostate cancer.
• At present, there are five oral drugs available to treat ED — Sildenafil (Viagra), avanafil (Stendra), vardenafil (Levitra, Staxyn), and tadalafil (Cialis). A number of pharmaceutical companies are investigating new treatments for ED, and many new options may be forthcoming.
• Uprima(apomorphine) that works by stimulating the brain chemical dopamine, which heightens sexual interest and sensations. Currently, clinical trials are also being conducted on a nasal spray form of this drug, which may cause less nausea.
• Topiglan uses the drug (alprostadil) that is injected sold under the brand names Caverject, Edex and Prostin VR—as well as a suppository-form of alprostadil, sold under the name MUSE, are at patients’ disposal. Melanocortin activators like the drug (PT-141) that acts through the central nervous system. Gene therapy is a novel therapy that would deliver genes, which will produce products or proteins that may not be operating properly in the penile tissue of men with ED.
• Replacement of the proteins may also result in erectile function improvement. But Gene therapy may take a long time for regulatory approval and for the public acceptance.
• Viagra drugs are dominating in the erectile dysfunction market. Levitra (vardenafil) from Bayer AG and Cialis (tadalafil) from Eli Lilly & Co. are known to be the competitors for Viagra globally and after the patent expiration of these drugs, the other drugs such as Zydena (udenafil), Stendra/Spedra, and Vitaros (Alprostadil Cream) are expected to capture the market growth during the next five years.
• Oral phosphodiesterase type 5 (PDE-5) inhibitors are commonly used in erectile dysfunction drugs across the globe. Further, Zydena containing udenafil, a PDE-5 inhibitor is manufactured and sold by Dong-A Pharmaceutical Co. Ltd. is expected to produce increased growth.
• This drug is distinguished from other PDE 5 inhibitors because of its longer duration of action and fewer incidences of side effects including vision disturbances and muscle pain.
• However, it has been found that about 50 drug molecules are currently in clinical trials, among which few drugs are expected to launch owing to increase in erectile dysfunction market proportionally. There are also medical devices like the Elator, which is approved by the Food and Drug Administration (FDA) and it is custom-made based on a patient’s girth and shaft with medical-grade silicone.
• Global erectile dysfunction drugs market continues to witness positive growth owing to the increased occurrence of chronic diseases, increase in lifestyle changes among the young population, rising geriatric population with the increase in the prevalence of erectile dysfunction would be expected to fuel demand erectile dysfunction drugs.
• The market of erectile dysfunction drugs steered by increasing generic product launch by local vendors, possible patent expires of erectile dysfunction drugs are anticipated, and promising product pipeline clinical developments are expected to propel the market for erectile dysfunction drugs.
• However, the availability of several counterfeit drugs, side effects associated with the use of erectile dysfunction drugs, a social taboo accomplice with erectile dysfunction in developing economies may hinder the growth of the erectile dysfunction drugs market.
• Erectile dysfunction therapeutics also called as impotence, is nothing but the inability or a form of sexual dysfunction where a man cannot retain a firm erection of the penis for coitus.
• Erectile dysfunction is more likely to affect people with blood clots, low blood pressure, and heart problems. It can be cured with appropriate medications.
• The predisposing factors are tobacco usage, injuries, overweight, drug and alcohol use. And medications include antidepressants, antihistamines and also include medications to treat high blood pressure, and pain or prostate cancer.
• At present, there are five oral drugs available to treat ED — Sildenafil (Viagra), avanafil (Stendra), vardenafil (Levitra, Staxyn), and tadalafil (Cialis). A number of pharmaceutical companies are investigating new treatments for ED, and many new options may be forthcoming.
• Uprima(apomorphine) that works by stimulating the brain chemical dopamine, which heightens sexual interest and sensations. Currently, clinical trials are also being conducted on a nasal spray form of this drug, which may cause less nausea.
• Topiglan uses the drug (alprostadil) that is injected sold under the brand names Caverject, Edex and Prostin VR—as well as a suppository-form of alprostadil, sold under the name MUSE, are at patients’ disposal. Melanocortin activators like the drug (PT-141) that acts through the central nervous system. Gene therapy is a novel therapy that would deliver genes, which will produce products or proteins that may not be operating properly in the penile tissue of men with ED.
• Replacement of the proteins may also result in erectile function improvement. But Gene therapy may take a long time for regulatory approval and for the public acceptance.
• Viagra drugs are dominating in the erectile dysfunction market. Levitra (vardenafil) from Bayer AG and Cialis (tadalafil) from Eli Lilly & Co. are known to be the competitors for Viagra globally and after the patent expiration of these drugs, the other drugs such as Zydena (udenafil), Stendra/Spedra, and Vitaros (Alprostadil Cream) are expected to capture the market growth during the next five years.
• Oral phosphodiesterase type 5 (PDE-5) inhibitors are commonly used in erectile dysfunction drugs across the globe. Further, Zydena containing udenafil, a PDE-5 inhibitor is manufactured and sold by Dong-A Pharmaceutical Co. Ltd. is expected to produce increased growth.
• This drug is distinguished from other PDE 5 inhibitors because of its longer duration of action and fewer incidences of side effects including vision disturbances and muscle pain.
• However, it has been found that about 50 drug molecules are currently in clinical trials, among which few drugs are expected to launch owing to increase in erectile dysfunction market proportionally. There are also medical devices like the Elator, which is approved by the Food and Drug Administration (FDA) and it is custom-made based on a patient’s girth and shaft with medical-grade silicone.
• Global erectile dysfunction drugs market continues to witness positive growth owing to the increased occurrence of chronic diseases, increase in lifestyle changes among the young population, rising geriatric population with the increase in the prevalence of erectile dysfunction would be expected to fuel demand erectile dysfunction drugs.
• The market of erectile dysfunction drugs steered by increasing generic product launch by local vendors, possible patent expires of erectile dysfunction drugs are anticipated, and promising product pipeline clinical developments are expected to propel the market for erectile dysfunction drugs.
• However, the availability of several counterfeit drugs, side effects associated with the use of erectile dysfunction drugs, a social taboo accomplice with erectile dysfunction in developing economies may hinder the growth of the erectile dysfunction drugs market.
